Maxim Group began coverage on shares of BioHarvest Sciences (NASDAQ:BHST – Free Report) in a report published on Wednesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $12.00 price objective on the stock.
Separately, HC Wainwright started coverage on shares of BioHarvest Sciences in a report on Friday, December 6th. They issued a “buy” rating and a $14.00 price target on the stock.
Read Our Latest Research Report on BioHarvest Sciences
BioHarvest Sciences Price Performance
About BioHarvest Sciences
BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.
Further Reading
- Five stocks we like better than BioHarvest Sciences
- How to Effectively Use the MarketBeat Ratings Screener
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- How to Start Investing in Real Estate
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- Which Wall Street Analysts are the Most Accurate?
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for BioHarvest Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioHarvest Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
